secwatch / observer
8-K filed November 12, 2024, 6:59 PM ET ticker PACB CIK 0001299130
leadership confidence high sentiment neutral materiality 0.50

Pacific Biosciences CCO Jeff Eidel to depart Nov 15 amid commercial restructuring

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jeff Eidel

Chief Commercial Officer
PACB · PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Effective
2024-11-15
Filed
November 12, 2024, 6:59 PM ET
On November 11, 2024, Pacific Biosciences of California, Inc. (the “Company”) notified Jeff Eidel that, in connection with an internal restructuring of the commercial organization, he would separate from his position as the Chief Commercial Officer on November 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeff Eidel departed as Chief Commercial Officer at PACIFIC BIOSCIENCES OF CALIFORNIA, INC..

Action
separated
Role
Chief Commercial Officer
Exact text from the filing
On November 11, 2024, Pacific Biosciences of California, Inc. (the “Company”) notified Jeff Eidel that, in connection with an internal restructuring of the commercial organization, he would separate from his position as the Chief Commercial Officer on November 15, 2024.
View on SEC.gov

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. filing history →

Source: SEC EDGAR
accession 0001299130-24-000185
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.